Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.47 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3888783 | 0.83 | NOTUM (0.36) | MAP2K1MAP2K2PRKCZIARS2NOTUM | |
| SCHEMBL5474210 | 0.79 | MAP2K1 (0.46) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL5485309 | 0.78 | MAP2K1 (0.45) | MAP2K1MAP2K2PRKCZIARS2IDO1 | |
| SCHEMBL3887238 | 0.77 | MAP2K1 (0.47) | MAP2K1MAP2K2PRKCZIARS2IDO1 | |
| SCHEMBL3888625 | 0.76 | MAP2K1 (0.45) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL5485434 | 0.76 | MAP2K1 (0.45) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL3956955 | 0.76 | MAP2K1 (0.51) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL3895233 | 0.75 | MAP2K1 (0.43) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL3895505 | 0.75 | MAP2K1 (0.45) | MAP2K1MAP2K2PRKCZIARS2NOTUM | |
| SCHEMBL4225150 | 0.75 | MAP2K1 (0.42) | MAP2K1MAP2K2PRKCZIARS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103121996-A | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors | SERONO LAB | 2013-05-29 | — | — | CN | claimed |
| CN-103121996-A | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors | SERONO LAB | 2013-05-29 | — | — | CN | disclosed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| CN-101426766-A | Novel heteroaryl substituted arylaminopyridine derivatives as MEK inhibitors | SERONO LAB (CH) | 2009-05-06 | — | — | CN | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | NRAS, MAP3K5, MAP3K1 | MAP2K1 40/4885MAP2K2 27/4885PRKCZ 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.